Australian Biotechnology News

Stories about: Dyax

  • +

    Zenyth, MuriGen collaborate on inflammation targets 20/02/2006 12:22:56

    Zenyth Therapeutics (ASX:ZTL), formerly Amrad, and unlisted Walter and Eliza Hall Institute (WEHI) spinout MuriGen Therapeutics are to co-develop a new class of drugs that target arthritis and other inflammatory diseases.
  • +

    Zenyth licence to boost antibody targets 30/01/2006 13:31:14

    Zenyth Therapeutics (ASX:ZTL), formerly Amrad, has taken a licence from Massachusetts-based Dyax Corp, to use the US company's proprietary phage display libraries to develop antibody therapeutics for inflammation and cancer.
  • +

    Gene-IT takes sequencing, patent search service to internet 16/06/2004 15:46:22

    US firm Gene-IT is offering an internet version of its genomic/proteomic sequence search and analysis service, which also searches for information on who holds patents.
Additional Resources
Newsletter Subscription
Sign up for our Australian Life Scientist newsletters!
 
Jobs